<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7155909\results\search\disease\results.xml">
  <result pre="copyright protections.aln-publish-ahead-of-print-aln.0000000000003303.pdf Abstract Healthcare systems worldwide are responding to Coronavirus" exact="Disease" post="2019 (COVID-19), an emerging infectious syndrome caused by the"/>
  <result pre="worldwide are responding to Coronavirus Disease 2019 (COVID-19), an emerging" exact="infectious" post="syndrome caused by the Severe Acute Respiratory Syndrome Coronavirus"/>
  <result pre="are responding to Coronavirus Disease 2019 (COVID-19), an emerging infectious" exact="syndrome" post="caused by the Severe Acute Respiratory Syndrome Coronavirus 2"/>
  <result pre="Disease 2019 (COVID-19), an emerging infectious syndrome caused by the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with"/>
  <result pre="2019 (COVID-19), an emerging infectious syndrome caused by the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with COVID-19"/>
  <result pre="(COVID-19), an emerging infectious syndrome caused by the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with COVID-19 can"/>
  <result pre="an emerging infectious syndrome caused by the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) virus. Patients with COVID-19 can progress"/>
  <result pre="COVID-19 can progress from asymptomatic or mild illness to hypoxemic" exact="respiratory" post="failure or multisystem organ failure, necessitating intubation and intensive"/>
  <result pre="and potential therapeutics, with a focus on management of COVID-19â€&quot;associated" exact="respiratory" post="failure. The authors draw on literature from other viral"/>
  <result pre="COVID-19â€&quot;associated respiratory failure. The authors draw on literature from other" exact="viral" post="epidemics, treatment of acute respiratory distress syndrome, and recent"/>
  <result pre="authors draw on literature from other viral epidemics, treatment of" exact="acute" post="respiratory distress syndrome, and recent publications on COVID-19, as"/>
  <result pre="draw on literature from other viral epidemics, treatment of acute" exact="respiratory" post="distress syndrome, and recent publications on COVID-19, as well"/>
  <result pre="perioperative settings, based on current understanding of coronavirus biology and" exact="acute" post="respiratory distress syndrome pathophysiology. In December 2019, a novel"/>
  <result pre="settings, based on current understanding of coronavirus biology and acute" exact="respiratory" post="distress syndrome pathophysiology. In December 2019, a novel pneumonia"/>
  <result pre="on current understanding of coronavirus biology and acute respiratory distress" exact="syndrome" post="pathophysiology. In December 2019, a novel pneumonia syndrome was"/>
  <result pre="acute respiratory distress syndrome pathophysiology. In December 2019, a novel" exact="pneumonia" post="syndrome was identified in patients clustered around the Huanan"/>
  <result pre="respiratory distress syndrome pathophysiology. In December 2019, a novel pneumonia" exact="syndrome" post="was identified in patients clustered around the Huanan Seafood"/>
  <result pre="was used to identify a novel coronavirus, now known as" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in bronchoalveolar lavage"/>
  <result pre="used to identify a novel coronavirus, now known as Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in bronchoalveolar lavage fluid"/>
  <result pre="to identify a novel coronavirus, now known as Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2), in bronchoalveolar lavage fluid from"/>
  <result pre="identify a novel coronavirus, now known as Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2), in bronchoalveolar lavage fluid from three"/>
  <result pre="(SARS-CoV-2), in bronchoalveolar lavage fluid from three of these patients." exact="Infection" post="with SARS-CoV-2 leads to the syndrome of Coronavirus Disease"/>
  <result pre="three of these patients. Infection with SARS-CoV-2 leads to the" exact="syndrome" post="of Coronavirus Disease 2019 (COVID-19). Rapid international spread of"/>
  <result pre="patients. Infection with SARS-CoV-2 leads to the syndrome of Coronavirus" exact="Disease" post="2019 (COVID-19). Rapid international spread of this potentially lethal"/>
  <result pre="Pathogenesis Relative to the assortment of viruses that cause human" exact="upper respiratory tract infection," post="the group of viruses that cause lower respiratory tract"/>
  <result pre="Relative to the assortment of viruses that cause human upper" exact="respiratory" post="tract infection, the group of viruses that cause lower"/>
  <result pre="upper respiratory tract infection, the group of viruses that cause" exact="lower" post="respiratory tract infection is smaller, but includes influenza and"/>
  <result pre="respiratory tract infection, the group of viruses that cause lower" exact="respiratory" post="tract infection is smaller, but includes influenza and parainfluenza,"/>
  <result pre="infection, the group of viruses that cause lower respiratory tract" exact="infection" post="is smaller, but includes influenza and parainfluenza, respiratory syncytial"/>
  <result pre="respiratory tract infection is smaller, but includes influenza and parainfluenza," exact="respiratory" post="syncytial virus, cytomegalovirus, and hantavirus. These infections are mostly"/>
  <result pre="influenza and parainfluenza, respiratory syncytial virus, cytomegalovirus, and hantavirus. These" exact="infections" post="are mostly limited to tracheobronchitis in healthy individuals but"/>
  <result pre="respiratory syncytial virus, cytomegalovirus, and hantavirus. These infections are mostly" exact="limited" post="to tracheobronchitis in healthy individuals but can cause severe"/>
  <result pre="limited to tracheobronchitis in healthy individuals but can cause severe" exact="viral" post="pneumonias in immunocompromised patients. While influenza is one of"/>
  <result pre="patients. While influenza is one of the best-known causes of" exact="pneumonia" post="in the intensive care unit (ICU), this presentation is"/>
  <result pre="intensive care unit (ICU), this presentation is frequently related to" exact="bacterial" post="superinfection, such as with Staphylococcus aureus.4 Some of the"/>
  <result pre="such as with Staphylococcus aureus.4 Some of the rarity of" exact="viral pneumonia" post="can be attributed to the types of cells that"/>
  <result pre="as with Staphylococcus aureus.4 Some of the rarity of viral" exact="pneumonia" post="can be attributed to the types of cells that"/>
  <result pre="(like H1N1) target cells in the trachea and bronchi, influenza" exact="pneumonia" post="is particularly linked to avian strains (like H5N1) that"/>
  <result pre="particularly linked to avian strains (like H5N1) that skip the" exact="upper" post="respiratory epithelium and infect alveolar epithelial cells of the"/>
  <result pre="linked to avian strains (like H5N1) that skip the upper" exact="respiratory" post="epithelium and infect alveolar epithelial cells of the lower"/>
  <result pre="H5N1) that skip the upper respiratory epithelium and infect alveolar" exact="epithelial" post="cells of the lower respiratory tract.5 SARS-CoV-2 is a"/>
  <result pre="upper respiratory epithelium and infect alveolar epithelial cells of the" exact="lower" post="respiratory tract.5 SARS-CoV-2 is a beta-coronavirus, a family that"/>
  <result pre="respiratory epithelium and infect alveolar epithelial cells of the lower" exact="respiratory" post="tract.5 SARS-CoV-2 is a beta-coronavirus, a family that includes"/>
  <result pre="is a beta-coronavirus, a family that includes the original severe" exact="acute" post="respiratory syndrome (SARS) virus, as well as Middle East"/>
  <result pre="a beta-coronavirus, a family that includes the original severe acute" exact="respiratory" post="syndrome (SARS) virus, as well as Middle East respiratory"/>
  <result pre="beta-coronavirus, a family that includes the original severe acute respiratory" exact="syndrome" post="(SARS) virus, as well as Middle East respiratory syndrome-related"/>
  <result pre="acute respiratory syndrome (SARS) virus, as well as Middle East" exact="respiratory" post="syndrome-related coronavirus (MERS), and endemic human pathogens that are"/>
  <result pre="of lethal strains of SARS-CoV in 2002 and Middle East" exact="respiratory" post="syndrome-related coronavirus in 2012 have added to their notoriety.6"/>
  <result pre="in 2012 have added to their notoriety.6 SARS-CoV, Middle East" exact="respiratory" post="syndrome-related coronavirus, and SARS-CoV-2 all likely originated in bats,"/>
  <result pre="with SARS-CoV using civets as intermediary hosts and Middle East" exact="respiratory" post="syndrome-related coronavirus passing though camels. Pangolins, also known as"/>
  <result pre="and replication. The â€œcoronaâ€� description references the crown-like halo of" exact="viral" post="spike (S) proteins observed by electron microscopy (fig. 1)."/>
  <result pre="receptor, a trait shared with SARS, but not Middle East" exact="respiratory" post="syndrome-related coronavirus or more common endemic human coronaviruses such"/>
  <result pre="OC43 and HKU1.8,9 Angiotensin converting enzyme-2 is expressed in the" exact="lower" post="respiratory tract but not bronchi, as well as enterocytes"/>
  <result pre="and HKU1.8,9 Angiotensin converting enzyme-2 is expressed in the lower" exact="respiratory" post="tract but not bronchi, as well as enterocytes in"/>
  <result pre="angiotensin converting enzyme-2 dependence may explain the clinical presentations of" exact="lower" post="respiratory tract infection and enteritis in COVID-19. Angiotensin converting"/>
  <result pre="converting enzyme-2 dependence may explain the clinical presentations of lower" exact="respiratory" post="tract infection and enteritis in COVID-19. Angiotensin converting enzyme-2"/>
  <result pre="dependence may explain the clinical presentations of lower respiratory tract" exact="infection" post="and enteritis in COVID-19. Angiotensin converting enzyme-2 expression in"/>
  <result pre="explain the clinical presentations of lower respiratory tract infection and" exact="enteritis" post="in COVID-19. Angiotensin converting enzyme-2 expression in vascular endothelium"/>
  <result pre="infection and enteritis in COVID-19. Angiotensin converting enzyme-2 expression in" exact="vascular" post="endothelium and cardiac myocytes has also been implicated in"/>
  <result pre="vascular endothelium and cardiac myocytes has also been implicated in" exact="acute" post="cardiac injury resulting from COVID-19.11 In animal models, angiotensin"/>
  <result pre="converting enzyme-2, increased production of angiotensin II, and resulting increased" exact="pulmonary" post="vascular permeability.15 While SARS-CoV-2â€&quot;susceptible angiotensin converting enzyme-2 appears universally"/>
  <result pre="enzyme-2, increased production of angiotensin II, and resulting increased pulmonary" exact="vascular" post="permeability.15 While SARS-CoV-2â€&quot;susceptible angiotensin converting enzyme-2 appears universally expressed"/>
  <result pre="Fig. 1. SARS-CoV-2 virus particles visualized by transmission electron micrograph." exact="Viral" post="particles are shown in blue-green with yellow viral envelope."/>
  <result pre="electron micrograph. Viral particles are shown in blue-green with yellow" exact="viral" post="envelope. This image was captured and color-enhanced at the"/>
  <result pre="captured and color-enhanced at the National Institute of Allergy and" exact="Infectious" post="Diseases Integrated Research Facility (Fort Detrick, Frederick, Maryland) and"/>
  <result pre="and color-enhanced at the National Institute of Allergy and Infectious" exact="Diseases" post="Integrated Research Facility (Fort Detrick, Frederick, Maryland) and used"/>
  <result pre="Frederick, Maryland) and used under creative commons license agreement.107 After" exact="viral" post="binding to angiotensin converting enzyme-2, the virus may be"/>
  <result pre="directly fuse with the cell membrane (fig. 2). A positive-sense" exact="viral" post="RNA transcript is then translated by the host cell,"/>
  <result pre="cell, yielding two polypeptides. These polypeptides are subsequently divided by" exact="viral" post="proteases, yielding the viral replication machinery. Coronaviruses employ multiple"/>
  <result pre="These polypeptides are subsequently divided by viral proteases, yielding the" exact="viral" post="replication machinery. Coronaviruses employ multiple mechanisms to shield viral"/>
  <result pre="the viral replication machinery. Coronaviruses employ multiple mechanisms to shield" exact="viral" post="RNA from host detection and subsequent induction of antiviral"/>
  <result pre="including direct antagonism of interferon signaling proteins and replication of" exact="viral" post="RNA in double membrane vesicles.15 Nonetheless, COVID-19 strongly induces"/>
  <result pre="cytokines and chemokines including interleukin-2, interleukin-4, interleukin-7, interleukin-8, interleukin-10, interferon-Î³," exact="tumor" post="necrosis factor-Î±, and macrophage inflammatory protein-1-Î±, suggesting a broad"/>
  <result pre="tumor necrosis factor-Î±, and macrophage inflammatory protein-1-Î±, suggesting a broad" exact="type 1" post="and type 2 helper T-cell response.17 It remains uncertain"/>
  <result pre="and macrophage inflammatory protein-1-Î±, suggesting a broad type 1 and" exact="type 2" post="helper T-cell response.17 It remains uncertain to what extent"/>
  <result pre="helper T-cell response.17 It remains uncertain to what extent direct" exact="viral" post="cytotoxicity versus the host cytokine storm and other immune"/>
  <result pre="spike protein (S), which mediates receptor binding and fusion, the" exact="viral" post="membrane protein (M), and the nucleocapsid protein (N). After"/>
  <result pre="(M), and the nucleocapsid protein (N). After binding of the" exact="viral" post="spike protein to the angiotensin converting enzyme-2 (ACE2) receptor,"/>
  <result pre="potential target of chloroquine, which prevents endosomal acidification that triggers" exact="viral" post="membrane fusion. Chloroquine may also modify ACE2 terminal glycosylation"/>
  <result pre="may also modify ACE2 terminal glycosylation and inhibit coronavirus binding." exact="Viral" post="RNA is then transcribed to generate polyproteins pp1a and"/>
  <result pre="pp1ab that are cleaved by a protease to generate the" exact="viral" post="replication machinery. These polyproteins are cleaved to form replication-transcription"/>
  <result pre="are cleaved to form replication-transcription protein complexes (RTCs) by a" exact="viral" post="protease 3-chymotrypsin-like protease (3CLpro). 3CLpro has been postulated to"/>
  <result pre="3CLpro has been postulated to be a target of human" exact="immunodeficiency" post="virus protease inhibitors lopinavir or ritonavir, although in silico"/>
  <result pre="or ritonavir, although in silico studies have questioned this theory.108" exact="Viral" post="RNA is replicated and transcribed in double membraned vesicles"/>
  <result pre="RNA-dependent RNA polymerase that is the putative target of remdesivir." exact="Viral" post="mRNA is then translated and virions are assembled in"/>
  <result pre="After initial coronavirus infection, immune responses appear effective in controlling" exact="viral infection," post="suggesting that vaccines should be feasible. There were important"/>
  <result pre="from 4 to 7 days. Initial reports demonstrated rapid person-to-person" exact="viral" post="transmission, with the number of infected individuals doubling every"/>
  <result pre="with the number of infected individuals doubling every 7.4 days.20" exact="Viral" post="evolution patterns inferred from viral gene sequence variations suggest"/>
  <result pre="individuals doubling every 7.4 days.20 Viral evolution patterns inferred from" exact="viral" post="gene sequence variations suggest that much of the viral"/>
  <result pre="from viral gene sequence variations suggest that much of the" exact="viral" post="transmission that has occurred in the United States has"/>
  <result pre="less negative selective pressure.7 The majority of patients with COVID-19" exact="infection" post="present with fever as the first symptom. Other common"/>
  <result pre="The most commonly reported hematologic laboratory abnormalities with COVID-19 are" exact="leukopenia" post="and lymphopenia.17,22â€&quot;24212223 The cause of this leukopenia is not"/>
  <result pre="with COVID-19 are leukopenia and lymphopenia.17,22â€&quot;24212223 The cause of this" exact="leukopenia" post="is not well understood but could relate to bone"/>
  <result pre="this leukopenia is not well understood but could relate to" exact="bone marrow suppression," post="lymphocyte sequestration, or apoptosis.25 The clinical spectrum of COVID-19"/>
  <result pre="good prognosis, up to 15% of patients will develop pneumonia," exact="acute" post="respiratory distress syndrome (ARDS), cardiac injury, renal injury, or"/>
  <result pre="prognosis, up to 15% of patients will develop pneumonia, acute" exact="respiratory" post="distress syndrome (ARDS), cardiac injury, renal injury, or multiorgan"/>
  <result pre="to 15% of patients will develop pneumonia, acute respiratory distress" exact="syndrome" post="(ARDS), cardiac injury, renal injury, or multiorgan failure from"/>
  <result pre="patients with COVID-19 will require admission to the ICU and" exact="respiratory" post="support with noninvasive or invasive ventilation, or potentially extracorporeal"/>
  <result pre="anesthesiologists in the perioperative setting, some patients present with minimal" exact="respiratory" post="symptoms. In one of the initial case series, a"/>
  <result pre="may be transmitted via the fecalâ€&quot;oral route via contaminated surfaces.26" exact="Pneumonia" post="or abnormalities in chest computed tomography images were detected"/>
  <result pre="the fecalâ€&quot;oral route via contaminated surfaces.26 Pneumonia or abnormalities in" exact="chest" post="computed tomography images were detected in almost all hospitalized"/>
  <result pre="characteristic radiographic findings are ground glass opacities, which are typically" exact="bilateral" post="and peripheral, coexisting with consolidations or cord-like opacities.17,27,282627 As"/>
  <result pre="radiologic features are rare with COVID-19, such as lymphadenopathy, nodules," exact="pleural" post="effusions, or cavitation, and would potentially suggest other pathologies.28"/>
  <result pre="COVID-19, with limitations of sample collection and kit performance, the" exact="total" post="positive rate of reverse transcriptase-polymerase chain reaction for throat"/>
  <result pre="presentation.29 Serial reverse transcriptase-polymerase chain reaction testing and inclusion of" exact="lower" post="airway sampling can improve the sensitivity of testing. Commercially"/>
  <result pre="available molecular tests for endemic coronaviruses, such as the FilmArray" exact="Respiratory" post="Panel (BioFire Diagnostics, USA) do not detect SARS-CoV-229 currently."/>
  <result pre="reaction testing, computed tomography imaging has been proposed as a" exact="primary" post="tool for COVID-19 detection in hospitalized patients in epidemic"/>
  <result pre="may have normal computed tomography imaging.28 Thus, early in the" exact="disease" post="course, there may be no diagnostic sufficiently sensitive to"/>
  <result pre="pathologic findings are similar to those seen with coronavirus-associated severe" exact="acute" post="respiratory syndrome caused by SARS-CoV and Middle East respiratory"/>
  <result pre="findings are similar to those seen with coronavirus-associated severe acute" exact="respiratory" post="syndrome caused by SARS-CoV and Middle East respiratory syndromeâ€&quot;related"/>
  <result pre="are similar to those seen with coronavirus-associated severe acute respiratory" exact="syndrome" post="caused by SARS-CoV and Middle East respiratory syndromeâ€&quot;related coronavirus,"/>
  <result pre="severe acute respiratory syndrome caused by SARS-CoV and Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus, such as inflammatory infiltrates and hyaline membrane"/>
  <result pre="thick secretions likely causes decreased alveolar gas exchange predisposing to" exact="respiratory" post="failure, suggesting a potential role for airway clearance and"/>
  <result pre="in the treatment of COVID-19. The full ramifications of SARS-CoV-2" exact="infection" post="are yet to be understood. Early work points to"/>
  <result pre="communities relating to anxiety, isolation, frustration, stigma, and guilt.33 This" exact="disease" post="also poses increased risk to specific subpopulations, such as"/>
  <result pre="with other viruses suggests that variation in the dose of" exact="viral" post="inoculum, route of inoculation, and underlying immune status of"/>
  <result pre="the patient can lead to widely variable host responses.36 Higher" exact="viral" post="loads on random sampling identified individuals with greater symptom"/>
  <result pre="mortality in adenoviral pneumonia.38 At the same time, moderate SARS-CoV-2" exact="viral" post="loads can be detected in nasal swabs up to"/>
  <result pre="symptoms and in asymptomatic individuals.39 The attributable risk from higher" exact="viral" post="inocula is difficult to quantify in real-world settings, but"/>
  <result pre="inocula is difficult to quantify in real-world settings, but higher" exact="viral" post="loads in critically ill patients pose at least a"/>
  <result pre="early reported cases of COVID-19 are old age and underlying" exact="respiratory" post="disease.24 Again, the reasons for these age associations are"/>
  <result pre="decreased vaccine effectiveness, worse outcomes in the setting of influenza," exact="respiratory" post="syncytial virus, and herpes zoster infections,41 and have been"/>
  <result pre="outcomes in the setting of influenza, respiratory syncytial virus, and" exact="herpes zoster" post="infections,41 and have been demonstrated in mouse models of"/>
  <result pre="in the setting of influenza, respiratory syncytial virus, and herpes" exact="zoster" post="infections,41 and have been demonstrated in mouse models of"/>
  <result pre="is one biologic mechanism of aging, which primarily manifests as" exact="pulmonary" post="fibrosis but can also restrict leukocyte proliferation. It is"/>
  <result pre="conceivable that poor outcomes from COVID-19 could be linked to" exact="short" post="telomeres, as has been reported with pulmonary fibrosis, ARDS,"/>
  <result pre="be linked to short telomeres, as has been reported with" exact="pulmonary" post="fibrosis, ARDS, and sepsis.42,43 It is also possible that"/>
  <result pre="It is also possible that younger individuals may have differential" exact="susceptibility to" post="SARS-CoV-2. Interestingly, in the rat lung, angiotensin converting enzyme-2"/>
  <result pre="OC43 and SARS-CoV.45 This potentially protective cross-reactive immunity would be" exact="limited" post="by age and immunosenescence. If fecalâ€&quot;oral transmission resulted in"/>
  <result pre="age and immunosenescence. If fecalâ€&quot;oral transmission resulted in a milder" exact="gastroenteritis" post="presentation of SARS-CoV-2, it is also conceivable that children"/>
  <result pre="conceivable that children could be subsequently protected from the COVID-19" exact="respiratory" post="syndrome. While we currently can only speculate as to"/>
  <result pre="clues that will inform management and therapeutics. Management of COVID-19â€&quot;associated" exact="Respiratory" post="Failure While most patients with COVID-19 appear to have"/>
  <result pre="that will inform management and therapeutics. Management of COVID-19â€&quot;associated Respiratory" exact="Failure" post="While most patients with COVID-19 appear to have a"/>
  <result pre="most patients with COVID-19 appear to have a relatively mild" exact="disease" post="course, a subset will develop hypoxemic respiratory failure with"/>
  <result pre="a relatively mild disease course, a subset will develop hypoxemic" exact="respiratory" post="failure with imaging patterns consistent with diffuse viral pneumonitis,"/>
  <result pre="will develop hypoxemic respiratory failure with imaging patterns consistent with" exact="diffuse" post="viral pneumonitis, organizing pneumonia, or diffuse alveolar damage.28,46 The"/>
  <result pre="develop hypoxemic respiratory failure with imaging patterns consistent with diffuse" exact="viral" post="pneumonitis, organizing pneumonia, or diffuse alveolar damage.28,46 The true"/>
  <result pre="imaging patterns consistent with diffuse viral pneumonitis, organizing pneumonia, or" exact="diffuse" post="alveolar damage.28,46 The true incidence of severe pulmonary disease"/>
  <result pre="pneumonia, or diffuse alveolar damage.28,46 The true incidence of severe" exact="pulmonary" post="disease associated with SARS-CoV-2 is not yet clear, but"/>
  <result pre="or diffuse alveolar damage.28,46 The true incidence of severe pulmonary" exact="disease" post="associated with SARS-CoV-2 is not yet clear, but several"/>
  <result pre="by experience during the 2003 SARS-CoV and 2012 Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus outbreaks. The World Health Organization has published"/>
  <result pre="a practice guideline on the clinical management of COVID-19 severe" exact="respiratory" post="infection,49 and several other groups have also published practice"/>
  <result pre="with COVID-19â€&quot;associated ARDS is made more complex due to necessary" exact="infection" post="control interventions such as the use of isolation rooms"/>
  <result pre="SARS-CoV-2 from patients to healthcare workers has been reported, and" exact="infection" post="control is of primary importance to protect healthcare workers"/>
  <result pre="healthcare workers has been reported, and infection control is of" exact="primary" post="importance to protect healthcare workers and prevent further spread"/>
  <result pre="as an additional safety measure.50,51 In select patients with COVID-19â€&quot;associated" exact="respiratory" post="failure presenting with hypoxemia that is not adequately treated"/>
  <result pre="management guidelines, among others, suggest this trial should be of" exact="limited" post="duration (1â€‰h) to avoid unrecognized severe respiratory decompensation that"/>
  <result pre="should be of limited duration (1â€‰h) to avoid unrecognized severe" exact="respiratory" post="decompensation that requires emergent intervention. The use of high"/>
  <result pre="effect, and reduces the work of breathing in patients with" exact="acute" post="respiratory failure.55,56 High flow nasal cannula has been used"/>
  <result pre="and reduces the work of breathing in patients with acute" exact="respiratory" post="failure.55,56 High flow nasal cannula has been used to"/>
  <result pre="from other outbreaks to guide its use in COVID-19 associated" exact="respiratory" post="failure.49,57 In one study of 310 patients with ARDS"/>
  <result pre="randomized to the high flow nasal cannula arm had a" exact="lower" post="90-day mortality rate.58 Patients with moderate or severe ARDS"/>
  <result pre="as the ratio of oxygen saturation/fraction of inspired oxygen to" exact="respiratory" post="rate, may be helpful to predict clinical deterioration and"/>
  <result pre="cannula as an initial strategy for the treatment of COVID-19â€&quot;associated" exact="respiratory" post="failure appears reasonable when patients are closely monitored for"/>
  <result pre="failure appears reasonable when patients are closely monitored for worsening" exact="respiratory" post="distress. World Health Organization COVID-19 guidelines and others recommend"/>
  <result pre="use of noninvasive positive pressure ventilation in the management of" exact="acute" post="respiratory failure due to cardiogenic pulmonary edema and in"/>
  <result pre="of noninvasive positive pressure ventilation in the management of acute" exact="respiratory" post="failure due to cardiogenic pulmonary edema and in patients"/>
  <result pre="in the management of acute respiratory failure due to cardiogenic" exact="pulmonary" post="edema and in patients with chronic obstructive pulmonary disease"/>
  <result pre="failure due to cardiogenic pulmonary edema and in patients with" exact="chronic" post="obstructive pulmonary disease (COPD) exacerbation leading to respiratory acidosis,"/>
  <result pre="to cardiogenic pulmonary edema and in patients with chronic obstructive" exact="pulmonary" post="disease (COPD) exacerbation leading to respiratory acidosis, no recommendations"/>
  <result pre="cardiogenic pulmonary edema and in patients with chronic obstructive pulmonary" exact="disease" post="(COPD) exacerbation leading to respiratory acidosis, no recommendations have"/>
  <result pre="pulmonary edema and in patients with chronic obstructive pulmonary disease" exact="(COPD)" post="exacerbation leading to respiratory acidosis, no recommendations have been"/>
  <result pre="patients with chronic obstructive pulmonary disease (COPD) exacerbation leading to" exact="respiratory" post="acidosis, no recommendations have been made regarding the use"/>
  <result pre="to a needed intubation, and from lung injury caused by" exact="uncontrolled" post="high tidal volumes with noninvasive positive pressure ventilation.58,60,62 There"/>
  <result pre="high tidal volumes with noninvasive positive pressure ventilation.58,60,62 There are" exact="limited" post="data to suggest that when noninvasive positive pressure ventilation"/>
  <result pre="to patients with ARDS, failure rates and mortality may be" exact="lower" post="than when a conventional noninvasive positive pressure ventilation facemask"/>
  <result pre="While a helmet mask may be additionally beneficial from an" exact="infection" post="control perspective, this intervention is not widely available.63 Experience"/>
  <result pre="from the 2009 H1N1 influenza epidemic and the Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus epidemic also informs the recommendations for use"/>
  <result pre="observational study of the treatment of patients with Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus reported a greater than 90% failure rate"/>
  <result pre="patients with mild ARDS, those in whom COPD exacerbation or" exact="heart" post="failure may also be contributing to respiratory distress, and"/>
  <result pre="COPD exacerbation or heart failure may also be contributing to" exact="respiratory" post="distress, and when the patient is closely monitored for"/>
  <result pre="when the patient is closely monitored for improvement or worsening" exact="respiratory" post="distress.49,50 There is substantial concern that using noninvasive positive"/>
  <result pre="pressure ventilation or high flow nasal cannula in patients with" exact="viral" post="respiratory illness results in increased production of aerosolized virus"/>
  <result pre="ventilation or high flow nasal cannula in patients with viral" exact="respiratory" post="illness results in increased production of aerosolized virus particles,"/>
  <result pre="identified participation in tracheal intubation as a risk factor for" exact="viral" post="spread to healthcare workers, noninvasive ventilation was only identified"/>
  <result pre="cannula or continuous positive airway pressure.69,70 The authors postulated that" exact="lower" post="exhaled air dispersion from high flow nasal cannula or"/>
  <result pre="any method of oxygen delivery to a patient with COVID-19â€&quot;associated" exact="respiratory" post="distress can result in spread of virus-containing exhaled air,"/>
  <result pre="isolation precautions.51,71 Providers should be aware that coronaviruses can remain" exact="infectious" post="on inanimate surfaces for up to 9 days, and"/>
  <result pre="the choice of initial oxygen therapy for patients with COVID-19â€&quot;associated" exact="respiratory" post="failure, these patients should be closely monitored for deterioration"/>
  <result pre="a time when healthcare workers are at high risk for" exact="viral" post="transmission from infected patients (odds ratio, 6.6).66 It should"/>
  <result pre="as compared with usual oxygen therapy in patients with hypoxemic" exact="respiratory" post="failure.76 However, high flow nasal cannula may be of"/>
  <result pre="Caring for Patients with COVID-19 After intubation, management of COVID-19â€&quot;associated" exact="respiratory" post="failure is the same as in ARDS from other"/>
  <result pre="use in early moderate to severe ARDS, and more adverse" exact="cardiovascular" post="events in the paralysis arm of the study.82 With"/>
  <result pre="hypoxemia despite lung protective ventilation with best practices, there are" exact="limited" post="data to guide effectiveness of the use of extracorporeal"/>
  <result pre="ARDS.84 In a small case-control series during the Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus outbreak, use of extracorporeal membrane oxygenation for"/>
  <result pre="of extracorporeal membrane oxygenation for refractory hypoxemia was associated with" exact="lower" post="in-hospital mortality.85 Considering these data, it may be reasonable"/>
  <result pre="to properly manage such complex patients.49,50 If patients with COVID-19â€&quot;associated" exact="respiratory" post="failure develop superimposed septic shock, adherence to standard sepsis"/>
  <result pre="complex patients.49,50 If patients with COVID-19â€&quot;associated respiratory failure develop superimposed" exact="septic shock," post="adherence to standard sepsis treatment protocols is advised.49 Additional,"/>
  <result pre="is advised.49 Additional, nonevidence-based recommendations for the management of COVID-19â€&quot;associated" exact="respiratory" post="failure have been promulgated by a variety of guidelines"/>
  <result pre="variety of guidelines and published sources, largely focusing on minimizing" exact="viral" post="spread to healthcare workers or the environment. These recommendations"/>
  <result pre="that show promise. SARS-CoV-2 is an RNA virus, like human" exact="immunodeficiency" post="virus (HIV) and Ebola, and molecules developed for other"/>
  <result pre="clinical trial sponsored by the National Institute of Allergy and" exact="Infectious" post="Diseases (trial No. NCT04280705). This adaptive trial will be"/>
  <result pre="trial sponsored by the National Institute of Allergy and Infectious" exact="Diseases" post="(trial No. NCT04280705). This adaptive trial will be actively"/>
  <result pre="to inhibit SARS-CoV-2 at micromolar concentrations. This agent, which blocks" exact="virus infection" post="both at entry and postentry stages, has been used"/>
  <result pre="inhibit SARS-CoV-2 at micromolar concentrations. This agent, which blocks virus" exact="infection" post="both at entry and postentry stages, has been used"/>
  <result pre="control cohort, SARS-CoV-1 patients treated with combination lopinavir/ritonavir had significantly" exact="lower" post="risk of ARDS or death.89 The combination of lopinavir/ritonavir"/>
  <result pre="clinical trial is comparing patients randomized to lopinavir/ritonavir and the" exact="viral" post="fusion inhibitor arbidol (trial No. NCT04252885). As the optimal"/>
  <result pre="clinical trials whenever available. World Health Organization and Centers for" exact="Disease" post="Control and Prevention recommendations49,93 discourage the use of corticosteroids,"/>
  <result pre="discourage the use of corticosteroids, given the risk for precipitating" exact="infectious" post="and noninfectious complications, such as secondary bacterial infections or"/>
  <result pre="the risk for precipitating infectious and noninfectious complications, such as" exact="secondary" post="bacterial infections or hyperglycemia. Further, in Middle East respiratory"/>
  <result pre="risk for precipitating infectious and noninfectious complications, such as secondary" exact="bacterial infections" post="or hyperglycemia. Further, in Middle East respiratory syndromeâ€&quot;related coronavirus"/>
  <result pre="for precipitating infectious and noninfectious complications, such as secondary bacterial" exact="infections" post="or hyperglycemia. Further, in Middle East respiratory syndromeâ€&quot;related coronavirus"/>
  <result pre="as secondary bacterial infections or hyperglycemia. Further, in Middle East" exact="respiratory" post="syndromeâ€&quot;related coronavirus patients, steroid therapy was associated with delayed"/>
  <result pre="respiratory syndromeâ€&quot;related coronavirus patients, steroid therapy was associated with delayed" exact="viral" post="clearance and no improvement in survival.94 However, it can"/>
  <result pre="for select ARDS patients, such as those early in the" exact="disease" post="course or those with superimposed septic shock.96 COVID-19 patients"/>
  <result pre="superimposed septic shock.96 COVID-19 patients have multiple distinct radiologic patterns:" exact="diffuse" post="ground glass, reticulation, consolidation suggestive of pneumonitis, diffuse alveolar"/>
  <result pre="radiologic patterns: diffuse ground glass, reticulation, consolidation suggestive of pneumonitis," exact="diffuse" post="alveolar damage, and organizing pneumonia.46 In cryptogenic organizing pneumonia,"/>
  <result pre="suggestive of pneumonitis, diffuse alveolar damage, and organizing pneumonia.46 In" exact="cryptogenic organizing pneumonia," post="steroid administration has been suggested to prevent progression to"/>
  <result pre="steroid administration has been suggested to prevent progression to hypoxemic" exact="respiratory" post="failure in case series.97 At the same time, the"/>
  <result pre="steroids has been shown to be less relevant for organizing" exact="pneumonia" post="with an identified cause, as in COVID-19.97 Compared with"/>
  <result pre="COVID-19.97 Compared with steroids, patients treated with macrolides for mild" exact="cryptogenic organizing pneumonia" post="also demonstrated symptom resolution, albeit with higher relapse rates.98"/>
  <result pre="with steroids, patients treated with macrolides for mild cryptogenic organizing" exact="pneumonia" post="also demonstrated symptom resolution, albeit with higher relapse rates.98"/>
  <result pre="in a subset of patients, such as those with organizing" exact="pneumonia" post="patterns. Conclusions In the face of this rapidly emerging"/>
  <result pre="Even a partially effective antiviral could allow sufficient reduction in" exact="viral" post="load so that the immune system can recover and"/>
  <result pre="evades cellular and humoral immunity, sharply limiting vaccination approaches,101 SARS-CoV" exact="infection" post="appeared to induce broad and long-lasting immunity with less"/>
  <result pre="upon to provide supportive care while minimizing the risk of" exact="viral" post="transmission to themselves and others. Research Support This work"/>
  <result pre="San Francisco, California), BioFire Diagnostics (Salt Lake City, Utah), Thermo" exact="Fisher" post="(Waltham, Massachusetts). Dr. London reports ongoing financial relationships with"/>
  <result pre="York, New York), UpToDate (Wolters Kluwer, Philadelphia, Pennsylvania), and the" exact="American" post="Society of Anesthesiologists (Schaumburg, Illinois). The other authors declare"/>
  <result pre="Coronavirus I, Research T: A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019.N Engl J Med2020; 382: 727â€&quot;33. DOI:"/>
  <result pre="DOI: 10.1056/NEJMoa200101731978945 2.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: Summary of a report"/>
  <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and Prevention.JAMA2020DOI: 10.1001/jama.2020.2648 3.Johns Hopkins CSSE: Coronavirus COVID-19"/>
  <result pre="Global Cases.Available at: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed March 8, 2020. 4.Rynda-AppleARobinsonKMAlcornJFInfluenza and" exact="bacterial" post="superinfection: Illuminating the immunologic mechanisms of disease.Infect Immun2015; 83:"/>
  <result pre="disease.Infect Immun2015; 83: 3764â€&quot;70. DOI: 10.1128/IAI.00298-1526216421 5.van RielDMunsterVJde WitERimmelzwaanGFFouchierRAOsterhausADKuikenTHuman and" exact="avian influenza" post="viruses target different cells in the lower respiratory tract"/>
  <result pre="WitERimmelzwaanGFFouchierRAOsterhausADKuikenTHuman and avian influenza viruses target different cells in the" exact="lower" post="respiratory tract of humans and other mammals.Am J Pathol2007;"/>
  <result pre="and avian influenza viruses target different cells in the lower" exact="respiratory" post="tract of humans and other mammals.Am J Pathol2007; 171:1215â€&quot;2317717141"/>
  <result pre="step in understanding SARS pathogenesis.J Pathol2004; 203:631â€&quot;715141377 11.ZhengYYMaYTZhangJYXieXCOVID-19 and the" exact="cardiovascular" post="system.Nat Rev Cardiol2020DOI: 10.1038/s41569-020-0360-5 12.FerrarioCMJessupJChappellMCAverillDBBrosnihanKBTallantEADizDIGallagherPEEffect of angiotensin-converting enzyme inhibition"/>
  <result pre="2020. 14.XuHZhongLDengJPengJDanHZengXLiTChenQHigh expression of ACE2 receptor of 2019-nCoV on the" exact="epithelial" post="cells of oral mucosa.Int J Oral Sci2020; 12:832094336 15.de"/>
  <result pre="Wuhan, China.Lancet2020; 395:497â€&quot;506. DOI: 10.1016/S0140-6736(20)30183-531986264 18.ChannappanavarRZhaoJPerlmanST cell-mediated immune response to" exact="respiratory" post="coronaviruses.Immunol Res2014; 59:118â€&quot;2824845462 19.KhanolkarAHartwigSMHaagBAMeyerholzDKEppingLLHaringJSVargaSMHartyJTProtective and pathologic roles of the"/>
  <result pre="19.KhanolkarAHartwigSMHaagBAMeyerholzDKEppingLLHaringJSVargaSMHartyJTProtective and pathologic roles of the immune response to mouse" exact="hepatitis" post="virus type 1: Implications for severe acute respiratory syndrome.J"/>
  <result pre="response to mouse hepatitis virus type 1: Implications for severe" exact="acute" post="respiratory syndrome.J Virol2009; 83:9258â€&quot;7219570864 20.LiQGuanXWuPWangXZhouLTongYRenRLeungKSMLauEHYWongJYXingXXiangNWuYLiCChenQLiDLiuTZhaoJLiMTuWChenCJinLYangRWangQZhouSWangRLiuHLuoYLiuYShaoGLiHTaoZYangYDengZLiuBMaZZhangYShiGLamTTYWuJTKGaoGFCowlingBJYangBLeungGMFengZEarly transmission dynamics in Wuhan,"/>
  <result pre="to mouse hepatitis virus type 1: Implications for severe acute" exact="respiratory" post="syndrome.J Virol2009; 83:9258â€&quot;7219570864 20.LiQGuanXWuPWangXZhouLTongYRenRLeungKSMLauEHYWongJYXingXXiangNWuYLiCChenQLiDLiuTZhaoJLiMTuWChenCJinLYangRWangQZhouSWangRLiuHLuoYLiuYShaoGLiHTaoZYangYDengZLiuBMaZZhangYShiGLamTTYWuJTKGaoGFCowlingBJYangBLeungGMFengZEarly transmission dynamics in Wuhan, China,"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive study.Lancet2020; 395:507â€&quot;13. DOI: 10.1016/S0140-6736(20)30211-732007143"/>
  <result pre="Medical Treatment Expert Group for C: Clinical characteristics of coronavirus" exact="disease" post="2019 in China.N Engl J Med2020DOI: 10.1056/NEJMoa2002032 24.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics"/>
  <result pre="24.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China.JAMA2020DOI: 10.1001/jama.2020.1585 25.ChenRFChangJCYehWTLeeCHLiuJWEngHLYangKDRole of vascular cell adhesion"/>
  <result pre="2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA2020DOI: 10.1001/jama.2020.1585 25.ChenRFChangJCYehWTLeeCHLiuJWEngHLYangKDRole of" exact="vascular" post="cell adhesion molecules and leukocyte apoptosis in the lymphopenia"/>
  <result pre="of vascular cell adhesion molecules and leukocyte apoptosis in the" exact="lymphopenia" post="and thrombocytopenia of patients with severe acute respiratory syndrome"/>
  <result pre="cell adhesion molecules and leukocyte apoptosis in the lymphopenia and" exact="thrombocytopenia" post="of patients with severe acute respiratory syndrome (SARS).Microbes Infect2006;"/>
  <result pre="apoptosis in the lymphopenia and thrombocytopenia of patients with severe" exact="acute" post="respiratory syndrome (SARS).Microbes Infect2006; 8:122â€&quot;716182592 26.YeoCKaushalSYeoDEnteric involvement of coronaviruses:"/>
  <result pre="in the lymphopenia and thrombocytopenia of patients with severe acute" exact="respiratory" post="syndrome (SARS).Microbes Infect2006; 8:122â€&quot;716182592 26.YeoCKaushalSYeoDEnteric involvement of coronaviruses: Is"/>
  <result pre="the lymphopenia and thrombocytopenia of patients with severe acute respiratory" exact="syndrome" post="(SARS).Microbes Infect2006; 8:122â€&quot;716182592 26.YeoCKaushalSYeoDEnteric involvement of coronaviruses: Is faecal-oral"/>
  <result pre="(COVID-19): Relationship to duration of infection.Radiology2020: 200463DOI: 10.1148/radiol.202020046332077789 29.AiTYangZHouHZhanCChenCLvWTaoQSunZXiaLCorrelation of" exact="chest" post="CT and RT-PCR testing in coronavirus disease 2019 (COVID-19)"/>
  <result pre="10.1148/radiol.202020046332077789 29.AiTYangZHouHZhanCChenCLvWTaoQSunZXiaLCorrelation of chest CT and RT-PCR testing in coronavirus" exact="disease" post="2019 (COVID-19) in China: A report of 1014 cases.Radiology2020:"/>
  <result pre="Accessed March 17, 2020. 31.XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome.Lancet Respir Med2020DOI: 10.1016/S2213-2600(20)30076-X 32.TianSHuWNiuLLiuHXuHXiaoSYPulmonary pathology of"/>
  <result pre="March 17, 2020. 31.XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFSPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome.Lancet Respir Med2020DOI: 10.1016/S2213-2600(20)30076-X 32.TianSHuWNiuLLiuHXuHXiaoSYPulmonary pathology of early"/>
  <result pre="10.1016/S2213-2600(20)30076-X 32.TianSHuWNiuLLiuHXuHXiaoSYPulmonary pathology of early phase 2019 novel coronavirus (COVID-19)" exact="pneumonia" post="in two patients with lung cancer.J Thorac Oncol2020DOI: 10.1016/j.jtho.2020.02.010"/>
  <result pre="is urgently needed.Lancet Psychiatry2020; 7:228â€&quot;9. DOI: 10.1016/S2215-0366(20)30046-832032543 34.MichaelsMGLa HozRMDanziger IsakovLBlumbergEAKumarDGreenMPruettTLWolfeCRCoronavirus" exact="disease" post="2019: Implications of emerging infections for transplantation.Am J Transplant2020DOI:"/>
  <result pre="DOI: 10.1016/S2215-0366(20)30046-832032543 34.MichaelsMGLa HozRMDanziger IsakovLBlumbergEAKumarDGreenMPruettTLWolfeCRCoronavirus disease 2019: Implications of emerging" exact="infections" post="for transplantation.Am J Transplant2020DOI: 10.1111/ajt.15832 35.LiangWGuanWChenRWangWLiJXuKLiCAiQLuWLiangHLiSHeJCancer patients in SARS-CoV-2"/>
  <result pre="nationwide analysis in China.Lancet Oncol2020; 21:335â€&quot;732066541 36.Geiben-LynnRGreenlandJRFrimpong-BoatengKLetvinNLKinetics of recombinant adenovirus" exact="type 5," post="vaccinia virus, modified vaccinia ankara virus, and DNA antigen"/>
  <result pre="in China.Lancet Oncol2020; 21:335â€&quot;732066541 36.Geiben-LynnRGreenlandJRFrimpong-BoatengKLetvinNLKinetics of recombinant adenovirus type 5," exact="vaccinia" post="virus, modified vaccinia ankara virus, and DNA antigen expression"/>
  <result pre="21:335â€&quot;732066541 36.Geiben-LynnRGreenlandJRFrimpong-BoatengKLetvinNLKinetics of recombinant adenovirus type 5, vaccinia virus, modified" exact="vaccinia" post="ankara virus, and DNA antigen expression in vivo and"/>
  <result pre="Vaccine Immunol2008; 15:691â€&quot;618272665 37.HijanoDRBrazelton de CardenasJMaronGGarnerCDFerrolinoJADallasRHGuZHaydenRTClinical correlation of influenza and" exact="respiratory" post="syncytial virus load measured by digital PCR.PLoS One2019; 14:e022090831479459"/>
  <result pre="measured by digital PCR.PLoS One2019; 14:e022090831479459 38.GuLQuJSunBYuXLiHCaoBSustained viremia and high" exact="viral" post="load in respiratory tract secretions are predictors for death"/>
  <result pre="PCR.PLoS One2019; 14:e022090831479459 38.GuLQuJSunBYuXLiHCaoBSustained viremia and high viral load in" exact="respiratory" post="tract secretions are predictors for death in immunocompetent adults"/>
  <result pre="death in immunocompetent adults with adenovirus pneumonia.PLoS One2016; 11:e016077727532864 39.ZouLRuanFHuangMLiangLHuangHHongZYuJKangMSongYXiaJGuoQSongTHeJYenHLPeirisMWuJSARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patients.N Engl"/>
  <result pre="adults with adenovirus pneumonia.PLoS One2016; 11:e016077727532864 39.ZouLRuanFHuangMLiangLHuangHHongZYuJKangMSongYXiaJGuoQSongTHeJYenHLPeirisMWuJSARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patients.N Engl J Med2020DOI: 10.1056/NEJMc2001737"/>
  <result pre="with adenovirus pneumonia.PLoS One2016; 11:e016077727532864 39.ZouLRuanFHuangMLiangLHuangHHongZYuJKangMSongYXiaJGuoQSongTHeJYenHLPeirisMWuJSARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patients.N Engl J Med2020DOI: 10.1056/NEJMc2001737 40.ZhaoSLingKYanHZhongLPengXYaoSHuangJChenXAnesthetic"/>
  <result pre="10.1056/NEJMc2001737 40.ZhaoSLingKYanHZhongLPengXYaoSHuangJChenXAnesthetic management of patients with suspected 2019 novel coronavirus" exact="infection" post="during emergency procedures.JCardiothorac Vasc Anesth2020DOI: 10.1053/j.jvca.2020.02.039 41.CrookeSNOvsyannikovaIGPolandGAKennedyRBImmunosenescence and human"/>
  <result pre="78: 2166â€&quot;71. DOI: 10.1016/j.lfs.2005.09.03816303146 45.ChanKHChengVCWooPCLauSKPoonLLGuanYSetoWHYuenKYPeirisJSSerological responses in patients with severe" exact="acute" post="respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses"/>
  <result pre="2166â€&quot;71. DOI: 10.1016/j.lfs.2005.09.03816303146 45.ChanKHChengVCWooPCLauSKPoonLLGuanYSetoWHYuenKYPeirisJSSerological responses in patients with severe acute" exact="respiratory" post="syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E,"/>
  <result pre="DOI: 10.1016/j.lfs.2005.09.03816303146 45.ChanKHChengVCWooPCLauSKPoonLLGuanYSetoWHYuenKYPeirisJSSerological responses in patients with severe acute respiratory" exact="syndrome" post="coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43,"/>
  <result pre="45.ChanKHChengVCWooPCLauSKPoonLLGuanYSetoWHYuenKYPeirisJSSerological responses in patients with severe acute respiratory syndrome coronavirus" exact="infection" post="and cross-reactivity with human coronaviruses 229E, OC43, and NL63.Clin"/>
  <result pre="47.YangXYuYXuJShuHXiaJLiuHWuYZhangLYuZFangMYuTWangYPanSZouXYuanSShangYClinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational study.Lancet Respir"/>
  <result pre="Singapore.JAMA2020DOI: 10.1001/jama.2020.3204 49.collab: World Health Organiziation: Clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus (nCoV) infection is suspected.Interim"/>
  <result pre="10.1001/jama.2020.3204 49.collab: World Health Organiziation: Clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus (nCoV) infection is suspected.Interim GuidanceUpdated"/>
  <result pre="49.collab: World Health Organiziation: Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected.Interim GuidanceUpdated January"/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected.Interim GuidanceUpdated January 28, 2020. Available at:https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version).Mil Med Res2020; 7:4DOI: 10.1186/s40779-020-0233-632029004 51.WaxRSChristianMDPractical recommendations for"/>
  <result pre="managing patients with COVID-19 infections.Transl Perioper Pain Med2020; 7:216â€&quot;24 53.XiaJGZhaoJPChengZSHuYDuanJZhanQYNon-invasive" exact="respiratory" post="support for patients with novel coronavirus pneumonia: Clinical efficacy"/>
  <result pre="novel coronavirus pneumonia: Clinical efficacy and reduction in risk of" exact="infection" post="transmission.Chin Med J (Engl)2020DOI: 10.1097/CM9.0000000000000761 54.PengPWWongDTBevanDGardamMInfection control and anesthesia:"/>
  <result pre="J Anaesth2003; 50:989â€&quot;9714656775 55.MauriTTurriniCEroniaNGrasselliGVoltaCABellaniGPesentiAPhysiologic effects of high-flow nasal cannula in" exact="acute" post="hypoxemic respiratory failure.Am J Respir Crit Care Med2017; 195:1207â€&quot;1527997805"/>
  <result pre="50:989â€&quot;9714656775 55.MauriTTurriniCEroniaNGrasselliGVoltaCABellaniGPesentiAPhysiologic effects of high-flow nasal cannula in acute hypoxemic" exact="respiratory" post="failure.Am J Respir Crit Care Med2017; 195:1207â€&quot;1527997805 56.ParkeRLEcclestonMLMcGuinnessSPThe effects"/>
  <result pre="nasal cannula oxygen therapy on mortality and intubation rate in" exact="acute" post="respiratory failure: A systematic review and meta-analysis.Crit Care Med2017;"/>
  <result pre="cannula oxygen therapy on mortality and intubation rate in acute" exact="respiratory" post="failure: A systematic review and meta-analysis.Crit Care Med2017; 45:e449â€&quot;56."/>
  <result pre="Study Group; REVA Network: High-flow oxygen through nasal cannula in" exact="acute" post="hypoxemic respiratory failure.N Engl J Med2015; 372:2185â€&quot;9625981908 59.RocaOCaraltBMessikaJSamperMSztrymfBHernÃ¡ndezGGarcÃ­a-de-AciluMFratJPMasclansJRRicardJDAn index"/>
  <result pre="REVA Network: High-flow oxygen through nasal cannula in acute hypoxemic" exact="respiratory" post="failure.N Engl J Med2015; 372:2185â€&quot;9625981908 59.RocaOCaraltBMessikaJSamperMSztrymfBHernÃ¡ndezGGarcÃ­a-de-AciluMFratJPMasclansJRRicardJDAn index combining respiratory"/>
  <result pre="hypoxemic respiratory failure.N Engl J Med2015; 372:2185â€&quot;9625981908 59.RocaOCaraltBMessikaJSamperMSztrymfBHernÃ¡ndezGGarcÃ­a-de-AciluMFratJPMasclansJRRicardJDAn index combining" exact="respiratory" post="rate and oxygenation to predict outcome of nasal high-flow"/>
  <result pre="Respir Crit Care Med2019; 199:1368â€&quot;7630576221 60.RochwergBBrochardLElliottMWHessDHillNSNavaSNavalesiPAntonelliMBrozekJContiGFerrerMGuntupalliKJaberSKeenanSManceboJMehtaSRaoofSOfficial ERS/ATS clinical practice guidelines:" exact="Noninvasive" post="ventilation for acute respiratory failure.Eur Respir J2017; 50DOI: 10.1183/13993003.02426-2016"/>
  <result pre="Med2019; 199:1368â€&quot;7630576221 60.RochwergBBrochardLElliottMWHessDHillNSNavaSNavalesiPAntonelliMBrozekJContiGFerrerMGuntupalliKJaberSKeenanSManceboJMehtaSRaoofSOfficial ERS/ATS clinical practice guidelines: Noninvasive ventilation for" exact="acute" post="respiratory failure.Eur Respir J2017; 50DOI: 10.1183/13993003.02426-2016 61.BellaniGLaffeyJGPhamTMadottoFFanEBrochardLEstebanAGattinoniLBumbasirevicVPiquilloudLvan HarenFLarssonAMcAuleyDFBauerPRArabiYMRanieriMAntonelliMRubenfeldGDThompsonBTWriggeHSlutskyASPesentiAcollab: LUNG"/>
  <result pre="199:1368â€&quot;7630576221 60.RochwergBBrochardLElliottMWHessDHillNSNavaSNavalesiPAntonelliMBrozekJContiGFerrerMGuntupalliKJaberSKeenanSManceboJMehtaSRaoofSOfficial ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute" exact="respiratory" post="failure.Eur Respir J2017; 50DOI: 10.1183/13993003.02426-2016 61.BellaniGLaffeyJGPhamTMadottoFFanEBrochardLEstebanAGattinoniLBumbasirevicVPiquilloudLvan HarenFLarssonAMcAuleyDFBauerPRArabiYMRanieriMAntonelliMRubenfeldGDThompsonBTWriggeHSlutskyASPesentiAcollab: LUNG SAFE"/>
  <result pre="50DOI: 10.1183/13993003.02426-2016 61.BellaniGLaffeyJGPhamTMadottoFFanEBrochardLEstebanAGattinoniLBumbasirevicVPiquilloudLvan HarenFLarssonAMcAuleyDFBauerPRArabiYMRanieriMAntonelliMRubenfeldGDThompsonBTWriggeHSlutskyASPesentiAcollab: LUNG SAFE Investigators; ESICM Trials Group:" exact="Noninvasive" post="ventilation of patients with acute respiratory distress syndrome. Insights"/>
  <result pre="SAFE Investigators; ESICM Trials Group: Noninvasive ventilation of patients with" exact="acute" post="respiratory distress syndrome. Insights from the LUNG SAFE Study.Am"/>
  <result pre="Investigators; ESICM Trials Group: Noninvasive ventilation of patients with acute" exact="respiratory" post="distress syndrome. Insights from the LUNG SAFE Study.Am J"/>
  <result pre="Crit Care Med2017; 195:67â€&quot;7727753501 62.FratJPRagotSCoudroyRConstantinJMGiraultCPratGBoulainTDemouleARicardJDRazaziKLascarrouJBDevaquetJMiraJPArgaudLChakarianJCFartoukhMNseirSMercatABrochardLRobertRThilleAWPredictors of intubation in patients with" exact="acute" post="hypoxemic respiratory failure treated with a noninvasive oxygenation strategy.Crit"/>
  <result pre="Med2017; 195:67â€&quot;7727753501 62.FratJPRagotSCoudroyRConstantinJMGiraultCPratGBoulainTDemouleARicardJDRazaziKLascarrouJBDevaquetJMiraJPArgaudLChakarianJCFartoukhMNseirSMercatABrochardLRobertRThilleAWPredictors of intubation in patients with acute hypoxemic" exact="respiratory" post="failure treated with a noninvasive oxygenation strategy.Crit Care Med2018;"/>
  <result pre="mask on the rate of endotracheal intubation in patients with" exact="acute" post="respiratory distress syndrome: A randomized clinical trial.JAMA2016; 315:2435â€&quot;4127179847 64.RodrÃ­guezAFerriCMartin-LoechesIDÃ­azEMasclansJRGordoFSole-ViolÃ¡nJBodÃ­MAvilÃ©s-JuradoFXTreflerSMagretMMorenoGReyesLFMarin-CorralJYebenesJCEstebanAAnzuetoAAlibertiSRestrepoMIcollab:"/>
  <result pre="on the rate of endotracheal intubation in patients with acute" exact="respiratory" post="distress syndrome: A randomized clinical trial.JAMA2016; 315:2435â€&quot;4127179847 64.RodrÃ­guezAFerriCMartin-LoechesIDÃ­azEMasclansJRGordoFSole-ViolÃ¡nJBodÃ­MAvilÃ©s-JuradoFXTreflerSMagretMMorenoGReyesLFMarin-CorralJYebenesJCEstebanAAnzuetoAAlibertiSRestrepoMIcollab: Grupo"/>
  <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infection.Ann Intern Med2014; 160:389â€&quot;9724474051 66.TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures"/>
  <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infection.Ann Intern Med2014; 160:389â€&quot;9724474051 66.TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and"/>
  <result pre="Med2014; 160:389â€&quot;9724474051 66.TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of" exact="acute" post="respiratory infections to healthcare workers: A systematic review.PLoS One2012;"/>
  <result pre="160:389â€&quot;9724474051 66.TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of acute" exact="respiratory" post="infections to healthcare workers: A systematic review.PLoS One2012; 7:e3579722563403"/>
  <result pre="66.TranKCimonKSevernMPessoa-SilvaCLConlyJAerosol generating procedures and risk of transmission of acute respiratory" exact="infections" post="to healthcare workers: A systematic review.PLoS One2012; 7:e3579722563403 67.FowlerRAScalesDCIlanREvidence"/>
  <result pre="suggests the use of high-flow nasal cannula does not decrease" exact="hypoxia" post="when compared with conventional oxygen therapy in the peri-intubation"/>
  <result pre="a systematic review and meta-analysis.Crit Care Med2020DOI: 10.1097/CCM.0000000000004217 77.FanEDel SorboLGoligherECHodgsonCLMunshiLWalkeyAJAdhikariNKJAmatoMBPBransonRBrowerRGFergusonNDGajicOGattinoniLHessDManceboJMeadeMOMcAuleyDFPesentiARanieriVMRubenfeldGDRubinESeckelMSlutskyASTalmorDThompsonBTWunschHUlerykEBrozekJBrochardLJcollab:" exact="American" post="Thoracic Society, European Society of Intensive Care Medicine, and"/>
  <result pre="systematic review and meta-analysis.Crit Care Med2020DOI: 10.1097/CCM.0000000000004217 77.FanEDel SorboLGoligherECHodgsonCLMunshiLWalkeyAJAdhikariNKJAmatoMBPBransonRBrowerRGFergusonNDGajicOGattinoniLHessDManceboJMeadeMOMcAuleyDFPesentiARanieriVMRubenfeldGDRubinESeckelMSlutskyASTalmorDThompsonBTWunschHUlerykEBrozekJBrochardLJcollab: American" exact="Thoracic" post="Society, European Society of Intensive Care Medicine, and Society"/>
  <result pre="Care Medicine, and Society of Critical Care Medicine: An official" exact="American" post="Thoracic Society/European Society of Intensive Care Medicine/Society of Critical"/>
  <result pre="Medicine, and Society of Critical Care Medicine: An official American" exact="Thoracic" post="Society/European Society of Intensive Care Medicine/Society of Critical Care"/>
  <result pre="of Critical Care Medicine Clinical Practice Guideline: Mechanical ventilation in" exact="adult" post="patients with acute respiratory distress syndrome.Am J Respir Crit"/>
  <result pre="Medicine Clinical Practice Guideline: Mechanical ventilation in adult patients with" exact="acute" post="respiratory distress syndrome.Am J Respir Crit Care Med2017; 195:1253â€&quot;6328459336"/>
  <result pre="Clinical Practice Guideline: Mechanical ventilation in adult patients with acute" exact="respiratory" post="distress syndrome.Am J Respir Crit Care Med2017; 195:1253â€&quot;6328459336 78.GriffithsMJDMcAuleyDFPerkinsGDBarrettNBlackwoodBBoyleACheeNConnollyBDarkPFinneySSalamASilversidesJTarmeyNWiseMPBaudouinSVGuidelines"/>
  <result pre="Respir Crit Care Med2017; 195:1253â€&quot;6328459336 78.GriffithsMJDMcAuleyDFPerkinsGDBarrettNBlackwoodBBoyleACheeNConnollyBDarkPFinneySSalamASilversidesJTarmeyNWiseMPBaudouinSVGuidelines on the management of" exact="acute" post="respiratory distress syndrome.BMJ Open Respir Res2019; 6:e000420 79.GriffithsMFanEBaudouinSVNew UK"/>
  <result pre="Crit Care Med2017; 195:1253â€&quot;6328459336 78.GriffithsMJDMcAuleyDFPerkinsGDBarrettNBlackwoodBBoyleACheeNConnollyBDarkPFinneySSalamASilversidesJTarmeyNWiseMPBaudouinSVGuidelines on the management of acute" exact="respiratory" post="distress syndrome.BMJ Open Respir Res2019; 6:e000420 79.GriffithsMFanEBaudouinSVNew UK guidelines"/>
  <result pre="Respir Res2019; 6:e000420 79.GriffithsMFanEBaudouinSVNew UK guidelines for the management of" exact="adult" post="patients with ARDS.Thorax2019; 74:931â€&quot;331481634 80.MatthayMAZemansRLZimmermanGAArabiYMBeitlerJRMercatAHerridgeMRandolphAGCalfeeCSAcute respiratory distress syndrome.Nat Rev"/>
  <result pre="for the management of adult patients with ARDS.Thorax2019; 74:931â€&quot;331481634 80.MatthayMAZemansRLZimmermanGAArabiYMBeitlerJRMercatAHerridgeMRandolphAGCalfeeCSAcute" exact="respiratory" post="distress syndrome.Nat Rev Dis Primers2019; 5:1830872586 81.CavalcantiABSuzumuraÃ‰LaranjeiraLNPaisaniDMDamianiLPGuimarÃ£esHPRomanoERRegengaMMTaniguchiLNTTeixeiraCPinheiro de OliveiraRMachadoFRDiaz-QuijanoFAFilhoMSAMaiaISCaserEBFilhoWOBorgesMCMartinsPAMatsuiMOspina-TascÃ³nGAGiancursiTSGiraldo-RamirezNDVieiraSRRAssefMDGPHasanMSSzczeklikWRiosFAmatoMBPBerwangerORibeiro"/>
  <result pre="pressure (PEEP) vs low PEEP on mortality in patients with" exact="acute" post="respiratory distress syndrome: A randomized clinical trial.JAMA2017; 318:1335â€&quot;45. DOI:"/>
  <result pre="(PEEP) vs low PEEP on mortality in patients with acute" exact="respiratory" post="distress syndrome: A randomized clinical trial.JAMA2017; 318:1335â€&quot;45. DOI: 10.1001/jama.2017.1417128973363"/>
  <result pre="syndrome: A randomized clinical trial.JAMA2017; 318:1335â€&quot;45. DOI: 10.1001/jama.2017.1417128973363 82.MossMHuangDTBrowerRGFergusonNDGindeAAGongMNGrissomCKGundelSHaydenDHiteRDHouPCHoughCLIwashynaTJKhanALiuKDTalmorDThompsonBTUlysseCAYealyDMAngusDCcollab: National" exact="Heart" post="Ln, and Blood Institute PETAL Clinical Trials Network: Early"/>
  <result pre="clinical trial.JAMA2017; 318:1335â€&quot;45. DOI: 10.1001/jama.2017.1417128973363 82.MossMHuangDTBrowerRGFergusonNDGindeAAGongMNGrissomCKGundelSHaydenDHiteRDHouPCHoughCLIwashynaTJKhanALiuKDTalmorDThompsonBTUlysseCAYealyDMAngusDCcollab: National Heart Ln, and" exact="Blood" post="Institute PETAL Clinical Trials Network: Early neuromuscular blockade in"/>
  <result pre="Institute PETAL Clinical Trials Network: Early neuromuscular blockade in the" exact="acute" post="respiratory distress syndrome.N Engl J Med2019; 380:1997â€&quot;2008. DOI: 10.1056/NEJMoa190168631112383"/>
  <result pre="PETAL Clinical Trials Network: Early neuromuscular blockade in the acute" exact="respiratory" post="distress syndrome.N Engl J Med2019; 380:1997â€&quot;2008. DOI: 10.1056/NEJMoa190168631112383 83.CombesAHajageDCapellierGDemouleALavouÃ©SGuervillyCDa"/>
  <result pre="Trial Group, REVA, and ECMONet: Extracorporeal membrane oxygenation for severe" exact="acute" post="respiratory distress syndrome.N Engl J Med2018; 378:1965â€&quot;7529791822 84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane"/>
  <result pre="Group, REVA, and ECMONet: Extracorporeal membrane oxygenation for severe acute" exact="respiratory" post="distress syndrome.N Engl J Med2018; 378:1965â€&quot;7529791822 84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane oxygenation"/>
  <result pre="syndrome.N Engl J Med2018; 378:1965â€&quot;7529791822 84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane oxygenation for severe" exact="acute" post="respiratory distress syndrome and posterior probability of mortality benefit"/>
  <result pre="Engl J Med2018; 378:1965â€&quot;7529791822 84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane oxygenation for severe acute" exact="respiratory" post="distress syndrome and posterior probability of mortality benefit in"/>
  <result pre="Med2018; 378:1965â€&quot;7529791822 84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane oxygenation for severe acute respiratory distress" exact="syndrome" post="and posterior probability of mortality benefit in a post"/>
  <result pre="84.GoligherECTomlinsonGHajageDWijeysunderaDNFanEJÃ¼niPBrodieDSlutskyASCombesAExtracorporeal membrane oxygenation for severe acute respiratory distress syndrome and" exact="posterior" post="probability of mortality benefit in a post hoc Bayesian"/>
  <result pre="trial.JAMA2018; 320:2251â€&quot;930347031 85.AlshahraniMSSindiAAlshamsiFAl-OmariAEl TahanMAlahmadiBZeinAKhataniNAl-HameedFAlamriSAbdelzaherMAlghamdiAAlfousanFTashATashkandiWAlraddadiRLewisKBadaweeMArabiYMFanEAlhazzaniWExtracorporeal membrane oxygenation for severe Middle East" exact="respiratory" post="syndrome coronavirus.Ann Intensive Care2018; 8:329330690 86.GordonCJTchesnokovEPFengJYPorterDPGotteMThe antiviral compound remdesivir"/>
  <result pre="320:2251â€&quot;930347031 85.AlshahraniMSSindiAAlshamsiFAl-OmariAEl TahanMAlahmadiBZeinAKhataniNAl-HameedFAlamriSAbdelzaherMAlghamdiAAlfousanFTashATashkandiWAlraddadiRLewisKBadaweeMArabiYMFanEAlhazzaniWExtracorporeal membrane oxygenation for severe Middle East respiratory" exact="syndrome" post="coronavirus.Ann Intensive Care2018; 8:329330690 86.GordonCJTchesnokovEPFengJYPorterDPGotteMThe antiviral compound remdesivir potently"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus.J Biol Chem2020DOI: 10.1074/jbc.AC120.013056 87.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine effectively"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus.J Biol Chem2020DOI: 10.1074/jbc.AC120.013056 87.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine effectively inhibit"/>
  <result pre="Res2020DOI: 10.1038/s41422-020-0282-0 88.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread.Virol J2005; 2:6916115318 89.ChuCMChengVCHungIFWongMMChanKHChanKSKaoRYPoonLLWongCLGuanYPeirisJSYuenKYcollab: Group HUSS: Role of"/>
  <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: The application of lopinavir/ritonavir for the treatment"/>
  <result pre="The application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCR.J Korean Med Sci2020; 35:e79DOI: 10.3346/jkms.2020.35.e7932056407"/>
  <result pre="COVID-19 related liver damage.medRxiv2020: 2020.02.26.20026971DOI: 10.1101/2020.02.26.20026971 93.collab: U.S. Centers for" exact="Disease" post="Control and Prevention (CDC): Interim Clinical Guidance for Management"/>
  <result pre="Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus" exact="Disease" post="2019 (COVID-19).Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed March 7, 2020. 94.ArabiYMMandourahYAl-HameedFSindiAAAlmekhlafiGAHusseinMAJoseJPintoRAl-OmariAKharabaAAlmotairiAAl"/>
  <result pre="Group: Corticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndrome.Am J Respir Crit Care Med2018; 197:757â€&quot;6729161116 95.LewisSRPritchardMWThomasCMSmithAFPharmacological agents"/>
  <result pre="Respir Crit Care Med2018; 197:757â€&quot;6729161116 95.LewisSRPritchardMWThomasCMSmithAFPharmacological agents for adults with" exact="acute" post="respiratory distress syndrome.Cochrane Database Syst Rev2019; 7:CD00447731334568 96.VillarJFerrandoCMartÃ­nezDAmbrÃ³sAMuÃ±ozTSolerJAAguilarGAlbaFGonzÃ¡lez-HiguerasEConesaLAMartÃ­n-RodrÃ­guezCDÃ­az-DomÃ­nguezFJSerna-GrandePRivasRFerreresJBeldaJCapillaLTalletAAÃ±Ã³nJMFernÃ¡ndezRLGonzÃ¡lez-MartÃ­nJMcollab: Dexamethasone"/>
  <result pre="Crit Care Med2018; 197:757â€&quot;6729161116 95.LewisSRPritchardMWThomasCMSmithAFPharmacological agents for adults with acute" exact="respiratory" post="distress syndrome.Cochrane Database Syst Rev2019; 7:CD00447731334568 96.VillarJFerrandoCMartÃ­nezDAmbrÃ³sAMuÃ±ozTSolerJAAguilarGAlbaFGonzÃ¡lez-HiguerasEConesaLAMartÃ­n-RodrÃ­guezCDÃ­az-DomÃ­nguezFJSerna-GrandePRivasRFerreresJBeldaJCapillaLTalletAAÃ±Ã³nJMFernÃ¡ndezRLGonzÃ¡lez-MartÃ­nJMcollab: Dexamethasone in"/>
  <result pre="7:CD00447731334568 96.VillarJFerrandoCMartÃ­nezDAmbrÃ³sAMuÃ±ozTSolerJAAguilarGAlbaFGonzÃ¡lez-HiguerasEConesaLAMartÃ­n-RodrÃ­guezCDÃ­az-DomÃ­nguezFJSerna-GrandePRivasRFerreresJBeldaJCapillaLTalletAAÃ±Ã³nJMFernÃ¡ndezRLGonzÃ¡lez-MartÃ­nJMcollab: Dexamethasone in ARDS Network: Dexamethasone treatment for the" exact="acute" post="respiratory distress syndrome: A multicentre, randomised controlled trial.Lancet Respir"/>
  <result pre="96.VillarJFerrandoCMartÃ­nezDAmbrÃ³sAMuÃ±ozTSolerJAAguilarGAlbaFGonzÃ¡lez-HiguerasEConesaLAMartÃ­n-RodrÃ­guezCDÃ­az-DomÃ­nguezFJSerna-GrandePRivasRFerreresJBeldaJCapillaLTalletAAÃ±Ã³nJMFernÃ¡ndezRLGonzÃ¡lez-MartÃ­nJMcollab: Dexamethasone in ARDS Network: Dexamethasone treatment for the acute" exact="respiratory" post="distress syndrome: A multicentre, randomised controlled trial.Lancet Respir Med2020;"/>
  <result pre="8:267â€&quot;7632043986 97.BasarakoduKRAronowWSNairCKLakkireddyDKondurAKorlakuntaHValasareddiSLLemVSchullerDDifferences in treatment and in outcomes between idiopathic and" exact="secondary" post="forms of organizing pneumonia.Am J Ther2007; 14:422â€&quot;617890928 98.RadzikowskaEWiatrELangfortRBestryISkoczylasASzczepulska-WÃ³jcikEGawrylukDRudziÅ&quot;skiPChorostowska-WynimkoJRoszkowski-ÅšliÅ¼KCryptogenic organizing"/>
  <result pre="clarithromycin versus corticosteroids-Observational study.PLoS One2017; 12:e018473928945804 99.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="versus corticosteroids-Observational study.PLoS One2017; 12:e018473928945804 99.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="study.PLoS One2017; 12:e018473928945804 99.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China.JAMA Intern Med2020:e200994DOI: 10.1001/jamainternmed.2020.0994 100.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRRayASCihlarTSiegelDMackmanRLClarkeMOBaricRSDenisonMRCoronavirus"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China.JAMA Intern Med2020:e200994DOI: 10.1001/jamainternmed.2020.0994 100.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRRayASCihlarTSiegelDMackmanRLClarkeMOBaricRSDenisonMRCoronavirus susceptibility to"/>
  <result pre="disease 2019 pneumonia in Wuhan, China.JAMA Intern Med2020:e200994DOI: 10.1001/jamainternmed.2020.0994 100.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRRayASCihlarTSiegelDMackmanRLClarkeMOBaricRSDenisonMRCoronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease.mBio2018; 9DOI: 10.1128/mBio.00221-18 101.BurtonDRAhmedRBarouchDHButeraSTCrottySGodzikAKaufmannDEMcElrathMJNussenzweigMCPulendranBScanlanCNSchiefWRSilvestriGStreeckHWalkerBDWalkerLMWardABWilsonIAWyattRA blueprint"/>
  <result pre="Mol Immunol2004; 1:193â€&quot;816219167 103.RenLLWangYMWuZQXiangZCGuoLXuTJiangYZXiongYLiYJLiXWLiHFanGHGuXYXiaoYGaoHXuJYYangFWangXMWuCChenLLiuYWLiuBYangJWangXRDongJLiLHuangCLZhaoJPHuYChengZSLiuLLQianZHQinCJinQCaoBWangJWIdentification of a novel coronavirus causing severe" exact="pneumonia" post="in human: A descriptive study.Chin Med J (Engl)2020DOI: 10.1097/CM9.0000000000000722"/>
  <result pre="series.BMJ2020; 368:m60632075786 106.TienHCChughtaiTJogeklarACooperABBrennemanFElective and emergency surgery in patients with severe" exact="acute" post="respiratory syndrome (SARS).Can J Surg2005; 48:71â€&quot;415757044 107.NIAID: Novel Coronavirus"/>
  <result pre="368:m60632075786 106.TienHCChughtaiTJogeklarACooperABBrennemanFElective and emergency surgery in patients with severe acute" exact="respiratory" post="syndrome (SARS).Can J Surg2005; 48:71â€&quot;415757044 107.NIAID: Novel Coronavirus SARS-CoV-2.Available"/>
  <result pre="106.TienHCChughtaiTJogeklarACooperABBrennemanFElective and emergency surgery in patients with severe acute respiratory" exact="syndrome" post="(SARS).Can J Surg2005; 48:71â€&quot;415757044 107.NIAID: Novel Coronavirus SARS-CoV-2.Available at:"/>
 </snippets>
</snippetsTree>
